Seattle Children's Hospital
Facts
- HQ
- Seattle
- Sectors
- Healthcare, Pediatrics, Medical Research, Hospital
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Seattle Childrens Hospital Seattle business license
Rajeev Singh
Rajeev Singh is CEO of Accolade, the Seattle-based company providing millions of people and their families with an exceptional healthcare experience that is personal, data driven and value-based, so that they can live their healthiest lives. Last month was Rajeev’s sixth anniversary at Accolade – congratulations! Prior to joining Accolade, he co-founded Concur, the global leader in travel and expense management, in 1993. Concur went public (Nasdaq: CNQR) in 1998, and grew to more than $800mm in revenue, over 4,000 employees, and more than 25,000 customers before being acquired by SAP AG for $8.3 billion in 2014. Rajeev’s desire to…
Viome raises $54M to develop saliva-based cancer diagnostics and expand microbiome consumer business
Viome Life Sciences raised $54 million to advance cancer diagnostics and support its consumer microbiome testing and customized supplement business, bringing total funding to over $125 million while targeting $100M revenue and one million customers next year.
AI2 Adds Bioengineer Jenny Cronin to Incubator; Icosavax Names Bekiroglu, Russo and Two Board Members; Proprio’s CMO Browd Expands Role
AI2 hired bioengineer Jenny Cronin as a principal for its startup incubator, bringing experience from s2s Public Relations, NanoString, and a UW bioengineering Ph.D.; AI2 has incubated startups like Ozette, Modulus and MajorBoost. Seattle biotech Icosavax named Elizabeth Bekiroglu general counsel, Thomas Russo CFO, and added Heidi Kunz and Ann Veneman to its board; pediatric neurosurgeon Samuel Browd is taking partial leave from UW/Seattle Children’s to expand as CMO of surgical tech startup Proprio.
Nordstrom to sell Viome’s $199 Health Intelligence microbiome test online and in select stores in 2022
Nordstrom will sell Viome Life Sciences’ Viome Health Intelligence microbiome test for $199 online and in select stores in 2022, with the kit requiring a stool sample. Viome sequences RNA to profile gut microbes and offers AI-driven diet/supplement recommendations plus a $149/month supplement service, though its clinical claims rely on non–peer-reviewed data and have drawn outside skepticism.
AdaptX (formerly MDMetrix) raises $6M Series A led by Vulcan Capital to expand AI-driven healthcare data platform
AdaptX, formerly MDMetrix, raised $6 million in a Series A led by Vulcan Capital to expand its AI-driven platform that extracts insights from electronic medical records to improve clinical, financial and equity outcomes. The Seattle startup, founded by anesthesiologist Dr. Dan Low, has raised over $11 million total, employs about 20 people, and will use proceeds for hiring and product development.
Viome Life Sciences splits into Viome Consumer Services and Viome Health Sciences to separate products from diagnostics and therapeutics
Viome, now Viome Life Sciences, has split into two divisions: Viome Consumer Services for individualized diet and supplement products, and Viome Health Sciences to develop diagnostics, predictive biomarkers and therapeutics for chronic disease and cancer. The Bellevue startup, led by CEO Naveen Jain and backed by investors including Marc Benioff, has over 200,000 customers and expects $100 million in revenue next year.
Clayton, Dubilier & Rice buys majority stake in Vera Whole Health, valuing Seattle startup at $400 million
Private equity firm Clayton, Dubilier & Rice acquired a majority stake in Seattle-based primary care startup Vera Whole Health in a deal valuing the company at $400 million; Vera uses a per-member, per-month employer-paid model and operates centers in ten states. The partnership adds to CD&R's healthcare portfolio and follows Vera's $76 million in prior funding and reported employer healthcare cost reductions of 10–25%.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
Bain Capital and Crosspoint Capital to buy Seattle cybersecurity firm ExtraHop for $900 million; founders stay
Private equity firms Bain Capital and Crosspoint Capital will acquire Seattle cybersecurity startup ExtraHop for $900 million; the 14-year-old company, with about 1,000 customers and 500+ employees, reported $100 million ARR and expects 40% growth this year. Founders and current leaders will remain, the deal aims to accelerate growth and is expected to close this summer.
Brad Evans launches Contrib to auction athlete memorabilia online and boost charity fundraising
Former Seattle Sounders defender Brad Evans has launched Contrib, a digital fundraising startup that auctions athlete memorabilia and leverages social media and game-time hype to raise more money for charities than traditional in-person donations. Evans says building the tech company has been a steep learning curve and is giving him new, sometimes sleepless, challenges compared with his 12-year pro soccer career.
MicrobiomX raises $1M pre-seed to commercialize stool collection, processing and capsule-encapsulation device
Seattle startup MicrobiomX raised $1 million in a pre-seed round to develop a device that collects, processes and extrudes stool into capsules for clinical fecal microbiota transplantation and offers microbiome analysis services. The company, launched in 2020 from UW and Seattle Children’s Hospital research after a $50,000 CoMotion grant, aims to simplify messy current stool-processing methods used for FMT and autologous FMT.
Notch Therapeutics raises $85M Series A (total $91M) to fund stem cell–derived T cell therapies and open Seattle lab
Notch Therapeutics raised an $85 million Series A, bringing total funding to $91 million, to advance stem cell–derived T cell immunotherapies and expand with a new Seattle research lab. The 2018-founded biotech plans to grow from 35 to about 100 employees by end of 2022 and is collaborating with Allogene Therapeutics on treatments for blood cancers.
Opticyte raises $4.6M to test real-time Cell O2 Monitor for early sepsis-induced organ failure
UW spinout Opticyte raised $4.6 million — $2.9M in federal grants and $1.7M in seed funding — to test a non-invasive Cell O2 Monitor that measures cellular oxygen in real time to detect early organ failure from sepsis. The company will begin an observational study at Harborview Medical Center in May or June and use funding to hire staff and continue device development.
Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors
Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.
GentiBio raises $20M seed round, licenses Treg technologies from Seattle Children’s, BRI and MIGAL
Boston-based GentiBio raised $20 million in a seed funding round and signed licensing deals with Seattle Children’s Research Institute, Benaroya Research Institute (BRI), and MIGAL to develop engineered regulatory T cells for autoimmune, alloimmune, autoinflammatory, and allergic diseases.
Proprio raises $23M Series A led by DCVC to commercialize 3D "X‑ray‑like" surgical navigation system
Seattle startup Proprio raised $23 million in a Series A led by DCVC to develop a hardware‑software surgical navigation system that fuses real-time camera views with preoperative imaging to give surgeons a 3D “X‑ray‑like” view without radiation.
MDMetrix raises $1.1M from Vulcan Capital and Seattle investors to scale COVID-19 Mission Control
Seattle startup MDMetrix raised $1.1 million from Vulcan Capital and other local investors to expand use of its COVID-19 Mission Control software, which analyzes hospital operational data to improve capacity and patient treatment.
Vera Whole Health raises $10M from existing backers to expand advanced primary care across 26 clinics
Seattle-based Vera Whole Health raised $10 million from existing backers to expand its advanced primary care model, bringing total funding to $70 million since its 2008 founding; the company operates 26 clinics in 10 states and employs about 450 people. Vera offers health coaching alongside primary care and works with employers, payers and health systems, including clients like Seattle Children’s and Blue Cross & Blue Shield of Kansas City.
MDMetrix and TransformativeMed Offer Free COVID-19 Tracking Tools to Hospitals; Deployed at UW Medicine
Two Seattle startups, MDMetrix and TransformativeMed, are offering their combined COVID-19 patient-tracking and analysis tools free to hospitals so clinicians can spot treatment and spread trends across patient groups. Their systems are already in use at University of Washington Medicine to screen patients, track symptoms and labs, and report data to state health departments.
Doctors Without Data
Dr. Dan Low wanted to know how his patients were doing on a new drug. Getting the data was so painful, he decided to found his own software company to make it easier. On this episode of Health Tech: Dan's journey from career doctor to startup CEO and back, and what his experience says about the state of healthcare data. See omnystudio.com/listener for privacy information.
Seattle Startup Nexgenia Raises $2M to Broaden Polymer Reagent Technology for Immunotherapy Applications
Seattle biotech startup Nexgenia, led by CEO Ron Myers, raised $2 million to expand its polymer-based reagents for sorting cells in immunotherapy production to new applications. The funding, led by the W Fund and Washington Research Foundation, will support further research into diverse uses of their technology beyond cancer treatment.
